Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Oncolys BioPharma's Days Inventory or its related term are showing as below:
During the past 13 years, Oncolys BioPharma's highest Days Inventory was 351643.28. The lowest was 9.10. And the median was 51.97.
TSE:4588's Days Inventory is not ranked *
in the Biotechnology industry.
Industry Median: 183.195 * Ranked among companies with meaningful Days Inventory only.
Oncolys BioPharma's Days Inventory
stayed the same
from Jun. 2024 (0.00) to Dec. 2025 (0.00).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Oncolys BioPharma's Inventory Turnover for the
three
months ended in Dec. 2025 was 0.00.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Oncolys BioPharma (TSE:4588) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Oncolys BioPharma's Inventory Turnover for the
three
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Oncolys BioPharma's Inventory to Revenue for the
three
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Oncolys BioPharma Days Inventory Related Terms
Oncolys BioPharma Days Inventory Historical Data
* Premium members only.
The historical data trend for Oncolys BioPharma's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4588 vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Oncolys BioPharma's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncolys BioPharma Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncolys BioPharma's Days Inventory distribution charts can be found below:
* The bar in red indicates where Oncolys BioPharma's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncolys BioPharma (TSE:4588) has a Days Inventory of 0.00 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Oncolys BioPharma and its competitors. Over the past decade, Oncolys BioPharma's Days Inventory has ranged from 9.10 to 351,643.28. According to the industry distribution chart, Oncolys BioPharma ranks #999999 out of 638 companies in the Biotechnology industry.
Is Oncolys BioPharma's Days Inventory too high?
Oncolys BioPharma's current Days Inventory is 0.00. Over the past 10 years, this metric has ranged from a low of 9.10 to a high of 351,643.28. Based on the distribution chart, Oncolys BioPharma ranks #999999 out of 638 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oncolys BioPharma has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncolys BioPharma's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncolys BioPharma ranks #999999 out of 638 companies for Days Inventory. This places Oncolys BioPharma in the lower half of its industry. The industry median Days Inventory is 183.20. Historically, Oncolys BioPharma's own Days Inventory has ranged from 9.10 to 351,643.28 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Oncolys BioPharma and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncolys BioPharma's current Days Inventory is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncolys BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Oncolys BioPharma (TSE:4588) is currently considered Significantly Overvalued. The stock's GF Value™ is 円363.11, compared to a current price of 円2,620.00 — trading 621.5% above its estimated fair value. The current Days Inventory is 0.00. Oncolys BioPharma's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Oncolys BioPharma (TSE:4588), the current Days Inventory is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncolys BioPharma (TSE:4588) Overvalued in 2026?
Based on GuruFocus' analysis, Oncolys BioPharma stock appears to be overvalued.
The current stock price of 円2,620.00 is trading 621.5% above its estimated GF Value™ of 円363.11.
GuruFocus considers Oncolys BioPharma to be Significantly Overvalued.
Key valuation signals for TSE:4588:
Days Inventory: 0.00
GF Value™: 円363.11 vs. price of 円2,620.00 (621.5% above fair value)
No single metric tells the full story. See the TSE:4588 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncolys BioPharma Inc develops pharmaceutical products. The company is a biopharmaceutical company focused on developing therapies for cancer treatment. Their product pipeline includes various drug candidates such as Telomelysin (OBP-301) and OBP-702, aimed at addressing unmet medical needs in oncology. The company targets healthcare providers and institutions involved in cancer care and research.
40GF Score
Get the complete analysis for TSE:4588
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4588 has been successfully added to your 
